Maxime Roméo Kouadio, L. Boyvin, Gnogbo Alexis Bahi, V. Tchako, Gervais Melaine M’boh, A. Gnionsahé, A. Djaman
{"title":"Erythropoietin and the Role of Inflammation in Anaemia in Patients with Chronic Renal Living in Cote D’ivoire","authors":"Maxime Roméo Kouadio, L. Boyvin, Gnogbo Alexis Bahi, V. Tchako, Gervais Melaine M’boh, A. Gnionsahé, A. Djaman","doi":"10.9734/ijbcrr/2021/v30i530265","DOIUrl":null,"url":null,"abstract":"Introduction: Anemia is one of the most common complications of kidney failure. The kidney is responsible for the production of erythropoietin, a key hormone in erythropoiesis. Insufficient production of erythropoietin due to impaired kidney functions and also inflammation could explain this anemia. This study aimed at contributing to a better understanding of the mechanisms of erythropoietin in anemia observed in kidney failure. \nMethods: The study population consisted of 138 people: 92 with chronic renal failure (46 not on dialysis, 46 on hemodialysis) and 46 voluntaries as control without kidney failure. Serum concentrations of urea, creatinine, C-reactive protein (CRP), serum iron, ferritin and transferrin were determined using the Cobas C311 Hitachi machine. The erythropoietin assay was performed on the ELISA chain. \nResults: Lower mean values of EPO, increased CRP and decreased iron were observed in CKF patients (EPO: 5.66 ± 0.97 mIU / L; CRP: 45 ± 7.46 mg / l ; Iron: 12.46 ± 0.85 µmol / l), and patients under dialysis (EPO: 9 ± 0.51 mIU / L; CRP: 9 ± 2.66 mg / l; Iron: 10.07 ± 0.54 µmol / l) compared to controls (EPO: 18 ± 1.29 mIU / L; CRP: 2 ± 0.30 mg / l; Iron: 15.85 ± 0.56 µmol / l). \nConclusion: Anemia in chronic renal failure is thought to be due to an erythropoietin deficiency but also to an exacerbation of inflammation with a disruption of the iron status.","PeriodicalId":13920,"journal":{"name":"International Journal of Biochemistry Research & Review","volume":"25 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biochemistry Research & Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9734/ijbcrr/2021/v30i530265","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Anemia is one of the most common complications of kidney failure. The kidney is responsible for the production of erythropoietin, a key hormone in erythropoiesis. Insufficient production of erythropoietin due to impaired kidney functions and also inflammation could explain this anemia. This study aimed at contributing to a better understanding of the mechanisms of erythropoietin in anemia observed in kidney failure.
Methods: The study population consisted of 138 people: 92 with chronic renal failure (46 not on dialysis, 46 on hemodialysis) and 46 voluntaries as control without kidney failure. Serum concentrations of urea, creatinine, C-reactive protein (CRP), serum iron, ferritin and transferrin were determined using the Cobas C311 Hitachi machine. The erythropoietin assay was performed on the ELISA chain.
Results: Lower mean values of EPO, increased CRP and decreased iron were observed in CKF patients (EPO: 5.66 ± 0.97 mIU / L; CRP: 45 ± 7.46 mg / l ; Iron: 12.46 ± 0.85 µmol / l), and patients under dialysis (EPO: 9 ± 0.51 mIU / L; CRP: 9 ± 2.66 mg / l; Iron: 10.07 ± 0.54 µmol / l) compared to controls (EPO: 18 ± 1.29 mIU / L; CRP: 2 ± 0.30 mg / l; Iron: 15.85 ± 0.56 µmol / l).
Conclusion: Anemia in chronic renal failure is thought to be due to an erythropoietin deficiency but also to an exacerbation of inflammation with a disruption of the iron status.